AFM
ORKA

Anson Funds Management’s Oruka Therapeutics ORKA Stock Holding History

Anson Funds Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-56
Closed -$81K – 67
2014
Q4 		$81K Buy
+56
New +$84.4K 0.1% 80

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Anson Funds Management's ORKA Position: Q1 2015 in Review

Anson Funds Management sold out of Oruka Therapeutics (ORKA) in Q1 2015, closing a stake of 56 shares — an estimated $81K sold.

Anson Funds Management first reported a position in ORKA in Q4 2014 and held it in 1 quarter. The position peaked at $81K in Q4 2014. 13 funds tracked by Wall St. Rank hold ORKA as of Q1 2015.

  • Anson Funds Management reported no remaining Oruka Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Anson Funds Management sold 56 Oruka Therapeutics shares in Q1 2015, an estimated $81K.
  • Anson Funds Management first reported a position in Oruka Therapeutics in Q4 2014 and held it in 1 quarter.
  • Anson Funds Management's Oruka Therapeutics position peaked at $81K in Q4 2014.
  • 13 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2015.

Based on Anson Funds Management's 13F filing for Q1 2015, filed 15 May 2015.